In early May, a large investigation had confirmed the incredible effectiveness of the beyfortus in the serious forms of bronchiolitis. But new works, this time directed by a network of 125 pediatricians (bet), revealed that injection “Could also help reduce the overall burden of acute otitis average otitis. ”
Otitis: a reduction of 23.7 % observed
The Beyfortus keeps surprising doctors. While the monoclonal antibody marketed by Sanofi already reduced hospitalizations for serious bronchiolitis by 83 %, it would now seem to protect the ears of babies.
Indeed, a vast French survey conducted by the “bet” pediatrician network, and presented at the European European Pediatric Congress (ESPID) last week, revealed that the injection had reduced children from children under a year to winter 2024-2025 and 48 % among infants less than six months.
“We rarely hospitalize for otitis. But it is still the first cause of prescription of antibiotics”underlined Robert Cohen, pediatric infectiologist who participated in this study.
With these advances, the Sanofi laboratory now explores the potential links between bronchiolitis and asthma.
“We are sure that there is a part of the asthms that are linked to VRS infections, but on which genetic terrains, it’s another discussion”continues Dr. Cohen, before asserting that the development of this respiratory disease is “multifactorial“.
But what does Dr Gérald Kierzek think about these conclusions? Here is his opinion.
Yes, in the vaccine “before the epidemic season”
The medical director of True Medical is rather convinced by the effects of this injection on toddlers.
“The Beyfortus (Nirsevimab) is known for its effectiveness against the VRS (syncytial respiratory virus) responsible for bronchiolitis. However, 40% of otitis in infants are linked to a preliminary infection by the VRS. By blocking the virus, the beyfortus reduces ENT complications, whose average otitis (reduction from 20 to 30% of otitis in protected children)” he confides.
Good use of it? A single injection is recommended at the start of the winter season, during the months of October or November. “”This passive monoclonal antibody protection is effective for about 5 months. This treatment is also effective from birth, including in premature babies “, Specifies Dr Gérald Kierzek.
The expert also recommends administer this injection before the season of the syncytial respiratory virus (VRS), preferably before the age of three months. It must be associated with other protective measures, such as regular nose washing and effective ventilation of parts.
Be careful however: this protection should not be considered as a substitute for other essential vaccines, especially against pneumococcus and Haemophilus influenzae. “It is also important not to underestimate the evocative signs of otitis, such as unusual crying, fever or a persistent cough”, concludes Dr Gérald Kierzek.